Welcome to our dedicated page for Vyne Therapeutics SEC filings (Ticker: VYNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for VYNE Therapeutics Inc. (VYNE) provides direct access to the company’s regulatory disclosures as a Nasdaq-listed clinical-stage biopharmaceutical issuer. These documents include annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, which together outline VYNE’s financial condition, risk factors, clinical programs and material corporate events.
Through its filings, VYNE describes its focus on developing differentiated BET inhibitor therapies for chronic inflammatory and immune-mediated conditions, including programs such as the oral BD2-selective BET inhibitor VYN202 and the topical pan-BD BET inhibitor repibresib gel. Periodic reports discuss research and development spending, general and administrative expenses, royalty revenue from its agreement with LEO Pharma A/S for Finacea® foam, and cash runway expectations under various operating assumptions.
Current reports on Form 8-K highlight specific developments that may be important to investors. Examples include disclosures of quarterly and annual financial results, clinical trial updates that are furnished as exhibits, and governance changes such as director resignations. A notable Form 8-K filed on December 17, 2025 describes VYNE’s entry into an Agreement and Plan of Merger and Reorganization with Yarrow Bioscience, Inc. and a merger subsidiary. That filing summarizes the structure of the all-stock merger, the expected pro forma ownership split, planned stockholder approvals, and conditions to closing, as well as related financing arrangements and support agreements.
Other 8-K filings detail the company’s annual meeting voting results and confirm its continued listing of common stock on The Nasdaq Stock Market LLC under the symbol VYNE. Together, these filings allow readers to review how VYNE reports material events, manages its capital structure and describes its strategic review and merger plans.
On this page, AI-powered tools can help interpret complex sections of lengthy filings by highlighting key points, summarizing risk factor themes and explaining the implications of items such as merger agreements, clinical program disclosures and changes in governance. Users can quickly locate information about VYNE’s quarterly performance in Forms 10-Q, its annual overview and risk disclosures in Form 10-K, and specific events reported on Forms 8-K, while using AI-generated summaries as a guide to the underlying regulatory text.
VYNE Therapeutics agreed to merge with private Yarrow Bioscience through a transaction in which Yarrow stockholders will receive shares of VYNE common stock and Yarrow will become a wholly owned subsidiary. Based on the exchange ratio and planned financings, pre‑merger Yarrow stockholders are expected to own about 97% of the combined company, while current VYNE stockholders are expected to own about 3%.
Before closing, VYNE expects to pay its existing stockholders a cash dividend totaling approximately $14.5–$16.5 million. Yarrow has completed a $100 million Series A preferred financing and arranged a separate $100 million PIPE in pre‑closing Yarrow shares and pre‑funded warrants, with registration rights for VYNE shares after the merger. The deal, approved by both boards and expected to close in the second quarter of 2026, is subject to stockholder approvals, Nasdaq listing and registration statement effectiveness, and will leave Yarrow designating all directors and executive officers of the combined company.
VYNE Therapeutics Inc. reported that one of its non-employee directors received an annual stock option award on December 12, 2025, the date of the company’s annual meeting of stockholders. The option covers 20,000 shares of VYNE common stock with an exercise price of $0.3756 per share and a stated expiration date of December 11, 2035.
According to the filing, the option vests in full on December 12, 2026, provided the director continues to serve through that date. After this grant, the director beneficially owns 20,000 derivative securities directly, reflecting this stock option position.
A director of VYNE Therapeutics Inc. reported receiving an annual grant of stock options for 20,000 shares of common stock on December 12, 2025. The options have an exercise price of $0.3756, expire on December 11, 2035, and relate to 20,000 shares. According to the filing, the options vest on December 12, 2026, if the director continues to provide service through that date.
VYNE Therapeutics Inc. disclosed that a non-employee director received an annual stock option award on 12/12/2025. The grant covers 20,000 stock options to purchase common stock at an exercise price of $0.3756 per share and expires on 12/11/2035.
The shares underlying the option vest on 12/12/2026, subject to the director’s continuous service through that date. Following this grant, the director beneficially owns 20,000 derivative securities directly.
VYNE Therapeutics Inc. reported that a non-employee director received an annual stock option award on December 12, 2025, the date of the company’s annual meeting of stockholders. The filing shows the grant of 20,000 stock options to purchase VYNE common stock at an exercise price of $0.3756 per share. These options vest on December 12, 2026, conditioned on the director’s continuous service through that date, and are scheduled to expire on December 11, 2035. Following this transaction, the director is shown as beneficially owning 20,000 derivative securities, all held directly.
VYNE Therapeutics Inc. reported the results of its 2025 annual meeting of stockholders held on December 12, 2025, where all three proposals on the ballot were approved. Of the 33,286,422 shares outstanding as of the record date, 16,680,776 shares, or 50.1%, were present or represented by proxy, providing a bare majority quorum.
Stockholders elected Class I directors Elisabeth Sandoval Little and Steven Basta to serve until the 2028 annual meeting, with each nominee receiving more votes for than withheld, plus 11,377,870 broker non-votes. They also ratified the selection of Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024, by a vote of 15,296,776 for, 766,080 against, and 617,920 abstentions.
On an advisory basis, stockholders approved the compensation of the company’s named executive officers, with 4,566,359 votes for, 680,945 against, 55,602 abstentions, and 11,377,870 broker non-votes. Overall, the meeting confirmed the company’s board choices, auditor, and executive pay program.
VYNE Therapeutics reported Q3 results reflecting a clinical-stage pivot and tighter spending. Royalty revenues were $169 thousand, while operating expenses fell to $8.0 million from $13.2 million a year ago, yielding an operating loss of $7.8 million and a net loss of $7.3 million. For the nine months, net loss was $21.6 million.
Liquidity remained stable with $32.7 million in cash, cash equivalents and marketable securities as of September 30, 2025, no debt, and total assets of $36.1 million. Operating cash use was $29.4 million year‑to‑date; management believes existing resources fund operations for at least 12 months, and cost reductions are expected to extend runway into the first half of 2027.
Pipeline updates: the FDA imposed a partial clinical hold on VYN202 in April; dosing for females at two doses resumed in June, with a 12‑week dog toxicology study initiated to address male enrollment. VYNE terminated the Phase 1b psoriasis trial after unblinding seven subjects showed directional improvements and plans to advance VYN202 in other immune‑mediated diseases. The Phase 2b repibresib (VYN201) vitiligo study did not meet primary and key secondary endpoints; VYNE is seeking a partner. A strategic review, including potential partnerships or transactions, is ongoing.
VYNE Therapeutics Inc. furnished a press release announcing its financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 to an Item 2.02 Form 8-K and is incorporated by reference.
The Item 2.02 information and Exhibit 99.1 are being furnished, not filed, under the Exchange Act.
VYNE Therapeutics Inc. Chief Financial Officer Zeronda Tyler reported a Form 4 disclosing a non‑derivative disposition on 09/30/2025. The filing shows 3,420 shares of common stock were disposed of at a price of $0.335 per share. The filing explains these shares were withheld by the issuer to satisfy tax withholding obligations related to the vesting of restricted stock units. After the reported transaction, the reporting person beneficially owns 111,653 shares, held in a direct ownership form. The Form 4 is signed by an attorney‑in‑fact and contains no other transactions or derivative instruments.